eFFECTOR Therapeutics, Inc.

OTCPK:EFTR Stock Report

Market Cap: US$2.4k

eFFECTOR Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Seeking Alpha • Sep 14

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

eFFECTOR Therapeutics (NASDAQ:EFTR) on Wednesday said it had dosed the first patient in the second cohort of its phase 1b clinical trial of its investigational cancer therapy zotatifin for the potential treatment of COVID-19. The early-stage trial is assessing the safety and antiviral activity of a single dose of zotatifin in patients with mild to moderate COVID, and is being conducted in collaboration with the University of California, San Francisco, EFTR said in a statement. The trial is being conducted using a $5M cooperative agreement sponsored by the government-led Defense Advanced Research Projects Agency. The dosing of the first patient in the second cohort follows a positive recommendation of an independent data safety board which reviewed data from the first dose cohort, EFTR said. EFTR stock marginally higher in morning trading.
Seeking Alpha • Aug 09

eFFECTOR Therapeutics GAAP EPS of -$0.17

eFFECTOR Therapeutics press release (NASDAQ:EFTR): Q2 GAAP EPS of -$0.17. Grant Revenue of $2.01M (+191.3% Y/Y). The company had cash and cash equivalents, and short-term investments totaling $41.0 million as of June 30, 2022, compared to $45.7 million in cash and cash equivalents as of March 31, 2022
Seeking Alpha • Sep 12

eFFECTOR: Developing New Class Of Cancer Therapies

eFFECTOR Therapeutics is pioneering the development of a new class of oncology drugs known as STRIs. The STRI therapy is also being evaluated for COVID-19 at UCSF under a DARPA grant. The company’s stock commenced trading on Nasdaq on 8/26/2021 after merger with SPAC Locust Walk Acquisition Corp. (LWAC).

CEO

eFFECTOR Therapeutics has no CEO, or we have no data on them.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 22:34
End of Day Share Price 2026/05/21 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

eFFECTOR Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
Robert BurnsH.C. Wainwright & Co.
Mara GoldsteinMizuho Securities USA LLC